Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)
Launched by STUART WEINSTEIN · Mar 14, 2007
Trial Information
Current as of April 30, 2025
Terminated
Keywords
ClinConnect Summary
AIS is characterized by a lateral curvature of the spine greater than 10 degrees plus rotation of the spinal vertebrae. AIS is found in adolescents between the age of 10 and time of skeletal maturity. Progression of a spinal curve to 50 degrees suggests a high risk for continued curve progression throughout adulthood and usually indicates the need for spinal fusion surgery. Only about 10 percent of adolescents with AIS end up having curves that progress and require surgical intervention. While certain risk factors for curve progression have been identified, there is no reliable way of estim...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of AIS
- • Skeletally immature (Risser grade 0, 1, or 2)
- • Pre-menarchal or post-menarchal by no more than 1 year
- • Primary Cobb angle between 20 and 40 degrees
- • Curve apex caudal to T7 vertebrae
- • Physical and mental ability to adhere to bracing protocol
- • Ability to read and understand English, Spanish, or French
- • Documented insurance coverage and/or personal willingness to pay for treatment
- Exclusion Criteria:
- • Diagnosis of other musculoskeletal or developmental illness that might be responsible for the spinal curvature
- • History of previous surgical or orthotic treatment for AIS
About Stuart Weinstein
Stuart Weinstein is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic approaches, he leads initiatives that seek to explore and validate new treatment modalities across various health conditions. His dedication to ethical research practices and stringent regulatory compliance ensures that all trials are conducted with the highest standards of integrity and scientific rigor. Through collaborative partnerships with healthcare professionals and research institutions, Weinstein aims to contribute valuable insights to the medical community and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Philadelphia, Pennsylvania, United States
Rochester, New York, United States
Pittsburgh, Pennsylvania, United States
Toronto, Ontario, Canada
Saint Louis, Missouri, United States
Madera, California, United States
Cincinnati, Ohio, United States
Boston, Massachusetts, United States
Seattle, Washington, United States
Atlanta, Georgia, United States
Iowa City, Iowa, United States
Vancouver, British Columbia, Canada
Sacramento, California, United States
San Diego, California, United States
Wilmington, Delaware, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Lexington, Kentucky, United States
Minneapolis, Minnesota, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Albuquerque, New Mexico, United States
Salt Lake City, Utah, United States
Charlottesville, Virginia, United States
Montreal, Quebec, Canada
Patients applied
Trial Officials
Stuart L. Weinstein, MD
Principal Investigator
University of Iowa
Lori A. Dolan, PhD
Study Director
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials